中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

乙型肝炎病毒核心相关抗原的监测及临床意义

刘成 慕永平 杨宗国 陈晓蓉

引用本文:
Citation:

乙型肝炎病毒核心相关抗原的监测及临床意义

基金项目: 

上海市科学技术委员会医学引导类项目(10411963000); 

详细信息
  • 中图分类号: R512.62

Clinical significance of monitoring hepatitis B virus core-related antigens 

Research funding: 

 

  • 摘要:

    监测乙型肝炎病毒核心相关抗原(HBcrAg),能有效预测核苷(酸)类药物抗病毒治疗后产生的病毒学反弹及耐药风险,具有重要的临床实用价值。

     

  • [1]European Association for the Study of the Liver.EASL clinicalpractice guidelines:management of chronic hepatitis B[J].J Hepatol, 2009, 50 (2) :227-242.
    [2]Lai CL, Ratziu V, Yuen MF, et al.Viral hepatitis B[J].Lan-cet, 2003, 362:2089-2094.
    [3] 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].中华肝脏病杂志, 2011, 19 (1) :13-24.
    [4] Yuen MF, Wong DK, Sum SS, et al.Effect of lamivudinetherapy on the serum covalently closed circular (ccc) DNAof chronic hepatitis B infection[J].Am J Gastroenterol, 2005, 100 (5) :1099-1103.
    [5]Lok AS, McMahon BJ.Chronic hepatitis B:update of rec-ommendations[J].Hepatology, 2004, 39 (3) :857-861.
    [6]Rokuhara A, Matsumoto A, Tanaka Y, et al.Hepatitis B vi-rus RNA is measurable in serum and can be a new marker formonitoring lamivudine therapy[J].J Gastroenterol, 2006, 41 (8) :785-790.
    [7]Hatakeyama T, Noguchi C, Hiraga N, et al.Serum HBV RNAis a predictor of early emergence of the YMDD mutant in pa-tients treated with lamivudine[J].Hepatology, 2007, 45 (5) :1179-1186.
    [8]Usuda S, Okamoto H, Tsuda F, et al.An enzyme-linked im-munosorbent assay with monoclonal antibodies for the determi-nation of phosphorylated hepatitis B core protein (p21c) in ser-um[J].J Virol Methods, 1998, 72 (1) :95-103.
    [9]Kimura TA, Rokuhara Y, Sakamoto S, et al.Sensitive en-zyme immunoassay for hepatitis B virus core-related anti-gens and their correlation to virus load[J].J Clin Microbiol, 2002, 40 (2) :439-445.
    [10]Suzuki F, Miyakoshi H, Kobayashi M, et al.Correlation be-tween serum hepatitis B virus core-related antigen and in-trahepatic covalently closed circular DNA in chronic hepatitisB patients[J].J M Virol, 2009, 81 (1) :27-33.
    [11]Kimura T, Ohno N, Terada N, et al.Hepatitis B virus DNA-negative Dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich do-main[J].J Biol Chem, 2005, 280 (23) :21713-21719.
    [12]Rokuhara A, Tanaka E, Matsumoto A, et al.Clinical evalua-tion of a new enzyme immunoassay for hepatitis B virus core-related antigen;a marker distinct from viral DNA for moni-toring lamivudine treatment[J].J Viral Hepatol, 2003, 10 (4) :324-330.
    [13]Sung JJY, Wong ML, Bowden S, et al.Intrahepatic hepati-tis B virus covalently closed circular DNA can be a predictorof sustained response to therapy[J].Gastroenterology, 2005, 128 (7) :1890-1897.
    [14]Wong DK, Tanaka Y, Lai CL, et al.Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis Binfection[J].J Clin Microbiol, 2007, 45 (12) :3942-3947.
    [15]Wong DK, Tanaka Y, Lai CL, et al.Detection of hepatitis Bvirus core-related antigens as a marker for the monitoring ofviral activity during nucleoside analogue therapy[J].J Hepa-tol, 2006, 44 (suppl 2) :S192-S192.
    [16]Wong DK, Yuen MF, Tanaka Y, et al.Correlation betweenhepatitis B virus core-related antigens and intrahepatic cova-lently closed circular DNA levels[J].Hepatology, 2005, 42 (4) :712A.
    [17]Rokuhara A, Sun XH, Tanaka E, et al.Hepatitis B virus coreand core-related antigen quantitation in Chinese patientswith chronic genotype B and C hepatitis B virus infection[J].J Gastroen Hepatol, 2005, 20 (11) :1726-1730.
    [18]Rokuhara A, Tanaka E, Matsumoto A, et al.Clinical evalua-tion of a new enzyme immunoassay for hepatitis B virus core-related antigen:a marker distinct from viral DNA for moni-toring lamivudine treatment[J].J Viral Hepatitis, 2003, 10 (4) :324-330.
    [19]Marzano A, Gaia S, Ghisetti V, et al.Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence.Liver transpl, 2005, 11 (4) :402-409.
    [20]Werle-Lapostolle B, Bowden S, Locarnini S, et al.Persist-ence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J].Gastroen-terology, 2004, 126 (7) :1750-1758.
    [21]Hamada R, Nakao R, Hai N, et al.Hepatitis B virus core-related antigen as an indicator of safe discontinuation of lami-vudine therapy[J].Hepatology, 2006, 44 (4) :562A.
    [22]Matsumoto A, Tanaka E, Suzuki Y, et al.Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos (t) ide analogs in patients with chronic hepatitis B[J].Hepatol Res, 2012, 42 (2) :139-149.
    [23]Tanaka E, Matsumoto A, Suzuki F, et al.Measurement of hepatitis B virus core-related antigen is valuable for identif-ying patients who are at low risk of lamivudine resistance[J].Liver Int, 2006, 26 (1) :90-96.
    [24]Tanaka E, Matsumoto A, Yoshizawa K, et al.Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy[J].Intervirology, 2008, 51 (Suppl1) :3-6.
    [25]Shinkai N, Tanaka Y, Orito E, et al.Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus in-fection[J].Hepatol Res, 2006, 36 (4) :272-276.
    [26]Matsumoto A, Tanaka E, Minami M, et al.Low serum level of hepatitis B indicates unlikely reactivation core-related an-tigen of hepatitis after cessation of lamivudine therapy[J].Hepatol Res, 2007, 37 (8) :661-666.
    [27]Fujimoto M, Ichikawa T, Nakao K, et al.The significance of enzyme immunoassay for the assessment of hepatitis B virus core-related antigen following liver transplantation[J].Inter Med, 2009, 48 (18) :1577-1583.
    [28]Matsuzaki T, Ichikawa T, Otani M, et al.The significance of hepatitis B virus core-related antigen and covalently closed circular DNA as HBV-refection markers after liver transplan-tation[J].J Hepatol, 2010, 52 (Suppl1) :S183-S317.
    [29]Hosaka T, Suzuki F, Kobayashi M, et al.HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma dur-ing antiviral therapy[J].Liver Int, 2010, 30 (10) :1461-1470.
  • 加载中
计量
  • 文章访问数:  3379
  • HTML全文浏览量:  21
  • PDF下载量:  779
  • 被引次数: 0
出版历程
  • 出版日期:  2012-10-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回